| References |
1.
Simultaneous separation of hydrophobic and hydrophilic peptides with a silica hydride stationary phase using aqueous normal phase conditions.
R.I.Boysen et al., J. Chromatogr. A, 1218, 8021 (2011)
2.
Long-term efficacy and tolerability of once-yearly histrelin acetate subcutaneous implant in patients with advanced prostate cancer.
N.Shore et al., BJU Int., 109, 226 (2012)
3.
144 ROLE OF GnRH ON MOUSE PRE-IMPLANTATION EMBRYONIC DEVELOPMENT IN VITRO.
Merck Index, 15th ed., No. 4760, (2013)
4.
Gonadotropin-releasing hormone analog design. Structure-function studies toward the development of agonists and antagonists: rationale and perspective.
M.Montagner et al., Reprod. Fertil. Dev., 17, 222 (2004)
5.
Effects of a sustained release formulation of the gonadotrophin-releasing hormone agonist histrelin on serum concentrations of gonadotrophins and oestradiol, and ovarian LH/human chorionic gonadotrophin receptor content in the rat.
M.J.Karten and J.E.Rivier, Endocr. Rev., 7, 44 (1986)
6.
The effects of the GnRH agonist, [(imBzl)-D-His6, Pro9-NEt]-GnRH, on the response to stress in rats.
J.W.Gunnet et al., J. Endocrinol., 131, 211 (1991)
7.
Histrelin: in advanced prostate cancer.
M.J.Gibson and D.S.Kohtz, Contraception, 31, 91 (1985)
8.
Effects of the (imBzl)D-His6, Des-Gly analog of GnRH on gonadotropin and estradiol secretion in normal women.
E.D.Deeks, Drugs, 70, 623 (2010) |